SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations
SOHM Inc. (OTC PINK:SHMN) has announced the formation of a dedicated AI team to enhance its ABBIE (A Binding-based Integrase Enzyme) system and develop novel guide RNAs and RNA guided Integrase fusion proteins. The initiative aims to revolutionize genome editing and cell engineering technologies.
The AI team will utilize machine learning algorithms to optimize guide RNAs and Integrase-dCas fusion proteins design, improving the specificity, efficiency, and versatility of genome editing applications. The company plans to develop next-generation genome editing systems and create engineered cells producing custom exosomes with pharmaceutical properties.
According to COO Dr. David Aguilar, these custom exosomes will serve as targeted delivery vehicles for therapeutic agents, with applications in cancer therapy, regenerative medicine, and immunotherapy. The company aims to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues.
SOHM Inc. (OTC PINK:SHMN) ha annunciato la formazione di un team dedicato all'IA per migliorare il suo sistema ABBIE (A Binding-based Integrase Enzyme) e sviluppare nuove guide RNA e proteine fusione Integrasi guidate da RNA. L'iniziativa mira a rivoluzionare le tecnologie di editing genomico e ingegneria cellulare.
Il team di IA utilizzerà algoritmi di apprendimento automatico per ottimizzare il design delle guide RNA e delle proteine fusione Integrasi-dCas, migliorando la specificità, l'efficienza e la versatilità delle applicazioni di editing genomico. L'azienda prevede di sviluppare sistemi di editing genomico di nuova generazione e creare cellule ingegnerizzate che producono esomi personalizzati con proprietà farmaceutiche.
Secondo il COO Dr. David Aguilar, questi esomi personalizzati serviranno come veicoli di consegna mirati per agenti terapeutici, con applicazioni nella terapia oncologica, nella medicina rigenerativa e nell'immunoterapia. L'azienda mira a progettare esomi in grado di trasportare in modo efficiente farmaci, geni o molecole di RNA verso tessuti specifici.
SOHM Inc. (OTC PINK:SHMN) ha anunciado la formación de un equipo dedicado a la IA para mejorar su sistema ABBIE (A Binding-based Integrase Enzyme) y desarrollar nuevas guías de RNA y proteínas de fusión de Integrasa guiadas por RNA. La iniciativa tiene como objetivo revolucionar las tecnologías de edición del genoma y la ingeniería celular.
El equipo de IA utilizará algoritmos de aprendizaje automático para optimizar el diseño de guías de RNA y proteínas de fusión de Integrasa-dCas, mejorando la especificidad, eficiencia y versatilidad de las aplicaciones de edición del genoma. La empresa planea desarrollar sistemas de edición del genoma de próxima generación y crear células ingenierizadas que produzcan exosomas personalizados con propiedades farmacéuticas.
Según el COO Dr. David Aguilar, estos exosomas personalizados servirán como vehículos de entrega dirigidos para agentes terapéuticos, con aplicaciones en terapia contra el cáncer, medicina regenerativa e inmunoterapia. La empresa tiene como objetivo diseñar exosomas que puedan transportar de manera eficiente medicamentos, genes o moléculas de RNA a tejidos específicos.
SOHM Inc. (OTC PINK:SHMN)는 ABBIE (A Binding-based Integrase Enzyme) 시스템을 개선하고 새로운 가이드 RNA 및 RNA 유도 인테그라제 융합 단백질을 개발하기 위해 전담 AI 팀을 구성했다고 발표했습니다. 이 이니셔티브는 유전자 편집 및 세포 공학 기술을 혁신하는 것을 목표로 하고 있습니다.
AI 팀은 머신 러닝 알고리즘을 활용하여 가이드 RNA 및 인테그라제-dCas 융합 단백질 디자인을 최적화하여 유전자 편집 응용 프로그램의 특이성, 효율성 및 다재다능성을 향상시킬 것입니다. 회사는 차세대 유전자 편집 시스템을 개발하고 약리학적 특성을 가진 맞춤형 외소체를 생산하는 엔지니어링 세포를 만들 계획입니다.
COO인 David Aguilar 박사에 따르면, 이러한 맞춤형 외소체는 치료제의 표적 전달 수단으로 사용되며, 암 치료, 재생 의학 및 면역 요법에 적용될 수 있습니다. 회사는 약물, 유전자 또는 RNA 분자를 특정 조직으로 효율적으로 운반할 수 있는 외소체를 설계하는 것을 목표로 하고 있습니다.
SOHM Inc. (OTC PINK:SHMN) a annoncé la formation d'une équipe dédiée à l'IA pour améliorer son système ABBIE (A Binding-based Integrase Enzyme) et développer de nouveaux ARN guides et des protéines de fusion d'Intégrase guidées par ARN. L'initiative vise à révolutionner les technologies d'édition génomique et d'ingénierie cellulaire.
L'équipe IA utilisera des algorithmes d'apprentissage automatique pour optimiser la conception des ARN guides et des protéines de fusion Intégrase-dCas, améliorant ainsi la spécificité, l'efficacité et la polyvalence des applications d'édition génomique. L'entreprise prévoit de développer des systèmes d'édition génomique de nouvelle génération et de créer des cellules ingénierées produisant des exosomes personnalisés avec des propriétés pharmaceutiques.
Selon le COO Dr. David Aguilar, ces exosomes personnalisés serviront de véhicules de livraison ciblés pour des agents thérapeutiques, avec des applications en thérapie contre le cancer, en médecine régénérative et en immunothérapie. L'entreprise vise à concevoir des exosomes capables de transporter efficacement des médicaments, des gènes ou des molécules d'ARN vers des tissus spécifiques.
SOHM Inc. (OTC PINK:SHMN) hat die Gründung eines speziellen KI-Teams angekündigt, um sein ABBIE (A Binding-based Integrase Enzyme) System zu verbessern und neuartige Leit-RNAs sowie RNA-gesteuerte Integrase-Fusionsproteine zu entwickeln. Die Initiative zielt darauf ab, die Technologien zur Genbearbeitung und Zelltechnik zu revolutionieren.
Das KI-Team wird maschinelle Lernalgorithmen nutzen, um das Design von Leit-RNAs und Integrase-dCas-Fusionsproteinen zu optimieren, wodurch die Spezifität, Effizienz und Vielseitigkeit der Anwendungen zur Genbearbeitung verbessert werden. Das Unternehmen plant, Systeme zur Genbearbeitung der nächsten Generation zu entwickeln und gezielte Zellen zu schaffen, die maßgeschneiderte Exosomen mit pharmazeutischen Eigenschaften produzieren.
Laut COO Dr. David Aguilar werden diese maßgeschneiderten Exosomen als gezielte Lieferfahrzeuge für therapeutische Wirkstoffe dienen, mit Anwendungen in der Krebstherapie, regenerativen Medizin und Immuntherapie. Das Unternehmen hat das Ziel, Exosomen zu entwerfen, die Medikamente, Gene oder RNA-Moleküle effizient zu spezifischen Geweben transportieren können.
- Formation of specialized AI team to enhance genome editing capabilities
- Development of custom exosomes for targeted drug delivery
- Expansion into multiple therapeutic applications (cancer, regenerative medicine, immunotherapy)
- No immediate revenue impact mentioned
- Early-stage development with no proven commercial success
- No timeline provided for technology implementation
CHINO HILLS, CA / ACCESS Newswire / April 7, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, is proud to announce the formation of a dedicated AI team focused on enhancing the capabilities of the ABBIE (A Binding-based Integrase Enzyme) system and the design of novel guide RNAs and other RNA guided Integrase fusion proteins. This strategic initiative is set to further SOHM's mission of revolutionizing genome editing and cell engineering technologies and expanding the frontiers of genetic research.
The ABBIE system, developed by SOHM Inc., has already demonstrated significant potential in genome editing. By integrating artificial intelligence into our research and development processes, the new team will leverage advanced machine learning algorithms to optimize the design of guide RNAs and Integrase-dCas fusion proteins. This innovation aims to enhance the specificity, efficiency, and versatility of genome editing applications, paving the way for breakthroughs in gene therapy, agriculture, and synthetic biology.
"Our new AI team represents a significant investment in the future of genetic engineering," said Dr. David Aguilar, COO of SOHM Inc. "By harnessing the power of AI, we aim to accelerate our research and development processes, ultimately leading to more effective and targeted genome editing solutions. Aiding the ABBIE system is just the beginning of what we hope to achieve with this cutting-edge technology."
In addition to enhancing and creating new renditions of the ABBIE system, the AI team will explore other avenues in the realm of genome editing. These include the development of next-generation genome editing systems that can target previously inaccessible genomic regions, enhancing the safety profiles of gene editing tools, and creating engineered cells producing custom exosomes with pharmaceutical properties. The latter project will focus on engineering exosomes as targeted delivery vehicles for therapeutic agents, offering a novel approach to treating a variety of diseases at the cellular level.
The potential of custom exosomes extends to applications in cancer therapy, regenerative medicine, and immunotherapy. By utilizing AI-driven insights and ABBIE-based cell engineering, SOHM Inc. aims to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues, significantly improving the efficacy and safety of treatments.
"AI has the potential to transform how we approach genetic engineering and therapeutics," added Aguilar. "Our focus on the ABBIE system and custom exosomes is just the start. We are committed to pushing the boundaries of what's possible in genome editing and therapeutic delivery."
As SOHM Inc. embarks on this exciting new chapter, the company remains dedicated to advancing scientific knowledge and improving human health through innovative biotechnology solutions. The establishment of the AI team marks a significant milestone in SOHM's ongoing journey to lead the industry in genomic research and development.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com:
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the main purpose of SOHM's (SHMN) new AI team?
How will SHMN's ABBIE system benefit from artificial intelligence?
What are the therapeutic applications of SHMN's custom exosomes project?
How will SHMN's AI-driven exosome technology improve treatment delivery?
